Aristotle Capital Management’s Zimmer Biomet ZBH Stock Holding History

Aristotle Capital Management’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330K	Hold	3,833	–	–	﹤0.01%	185
2026 Q1	$347K	Hold	3,833	–	–	﹤0.01%	181
2025 Q4	$345K	Hold	3,833	–	–	﹤0.01%	182
2025 Q3	$378K	Hold	3,833	–	–	﹤0.01%	179
2025 Q2	$350K	Hold	3,833	–	–	﹤0.01%	176
2025 Q1	$434K	Hold	3,833	–	–	﹤0.01%	167
2024 Q4	$405K	Hold	3,833	–	–	﹤0.01%	173
2024 Q3	$414K	Hold	3,833	–	–	﹤0.01%	173
2024 Q2	$416K	Hold	3,833	–	–	﹤0.01%	168
2024 Q1	$506K	Hold	3,833	–	–	﹤0.01%	164
2023 Q4	$466K	Hold	3,833	–	–	﹤0.01%	159
2023 Q3	$430K	Hold	3,833	–	–	﹤0.01%	158
2023 Q2	$558K	Sell	3,833 -667	-15%	-$90.6K	﹤0.01%	155
2023 Q1	$581K	Hold	4,500	–	–	﹤0.01%	158
2022 Q4	$574K	Hold	4,500	–	–	﹤0.01%	163
2022 Q3	$470K	Hold	4,500	–	–	﹤0.01%	162
2022 Q2	$473K	Hold	4,500	–	–	﹤0.01%	163
2022 Q1	$576K	Sell	4,500 -135	-3%	-$16.3K	﹤0.01%	164
2021 Q4	$572K	Hold	4,635	–	–	﹤0.01%	167
2021 Q3	$659K	Hold	4,635	–	–	﹤0.01%	160
2021 Q2	$724K	Hold	4,635	–	–	﹤0.01%	158
2021 Q1	$720K	Hold	4,635	–	–	﹤0.01%	151
2020 Q4	$693K	Hold	4,635	–	–	﹤0.01%	154
2020 Q3	$613K	Hold	4,635	–	–	﹤0.01%	152
2020 Q2	$537K	Hold	4,635	–	–	﹤0.01%	150
2020 Q1	$455K	Hold	4,635	–	–	﹤0.01%	155
2019 Q4	$674K	Hold	4,635	–	–	﹤0.01%	149
2019 Q3	$618K	Sell	4,635 -16	-0.3%	-$2.07K	﹤0.01%	153
2019 Q2	$532K	Sell	4,651 -2	-0%	-$234	﹤0.01%	162
2019 Q1	$577K	Buy	4,653 +18	+0.4%	+$2.05K	﹤0.01%	156
2018 Q4	$467K	Hold	4,635	–	–	﹤0.01%	155
2018 Q3	$592K	Hold	4,635	–	–	﹤0.01%	155
2018 Q2	$501K	Hold	4,635	–	–	﹤0.01%	154
2018 Q1	$491K	Hold	4,635	–	–	﹤0.01%	159
2017 Q4	$543K	Hold	4,635	–	–	﹤0.01%	162
2017 Q3	$527K	Hold	4,635	–	–	﹤0.01%	134
2017 Q2	$578K	Hold	4,635	–	–	﹤0.01%	89
2017 Q1	$549K	Hold	4,635	–	–	0.01%	94
2016 Q4	$464K	Hold	4,635	–	–	﹤0.01%	93
2016 Q3	$585K	Hold	4,635	–	–	0.01%	89
2016 Q2	$542K	Hold	4,635	–	–	0.01%	89
2016 Q1	$480K	Hold	4,635	–	–	0.01%	97
2015 Q4	$462K	Hold	4,635	–	–	0.01%	105
2015 Q3	$423K	Hold	4,635	–	–	0.01%	109
2015 Q2	$492K	Hold	4,635	–	–	0.01%	107
2015 Q1	$529K	Hold	4,635	–	–	0.01%	109
2014 Q4	$510K	Hold	4,635	–	–	0.01%	113
2014 Q3	$452K	Hold	4,635	–	–	0.01%	120
2014 Q2	$467K	Hold	4,635	–	–	0.01%	139
2014 Q1	$426K	Hold	4,635	–	–	0.01%	121
2013 Q4	$419K	Hold	4,635	–	–	0.01%	115
2013 Q3	$370K	Hold	4,635	–	–	0.01%	121
2013 Q2	$337K	Buy	+4,635	New	+$347K	0.01%	118

Other funds holding ZBH

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aristotle Capital Management's ZBH Position: Q2 2026 in Review

Aristotle Capital Management held its Zimmer Biomet (ZBH) position steady in Q2 2026 at 3,833 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #185.

Aristotle Capital Management first reported a position in ZBH in Q2 2013 and has held it in 53 quarters since. The position peaked at $724K in Q2 2021. 907 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

Aristotle Capital Management held 3,833 shares of Zimmer Biomet worth $330K as of Q2 2026.
Aristotle Capital Management left its Zimmer Biomet share count unchanged in Q2 2026.
Zimmer Biomet made up ﹤0.01% of Aristotle Capital Management's portfolio in Q2 2026, its #185 holding.
Aristotle Capital Management first reported a position in Zimmer Biomet in Q2 2013 and has held it in 53 quarters since.
Aristotle Capital Management's Zimmer Biomet position peaked at $724K in Q2 2021.
907 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on Aristotle Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.